Uy Ear
Stock Analyst at Mizuho
(4.22)
# 471
Out of 5,182 analysts
83
Total ratings
50%
Success rate
18.86%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLMD Relmada Therapeutics | Maintains: Outperform | $10 → $19 | $7.29 | +160.63% | 3 | Mar 20, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $26 → $31 | $21.18 | +46.36% | 10 | Mar 13, 2026 | |
| QURE uniQure | Upgrades: Outperform | $12 → $35 | $15.38 | +127.57% | 8 | Mar 11, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $37 → $35 | $24.21 | +44.57% | 16 | Mar 2, 2026 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Outperform | $29 → $35 | $21.74 | +60.99% | 16 | Feb 23, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $146 → $175 | $128.89 | +35.77% | 11 | Dec 12, 2025 | |
| EOLS Evolus | Maintains: Outperform | $20 → $19 | $4.27 | +344.96% | 4 | Dec 2, 2025 | |
| ALKS Alkermes | Maintains: Outperform | $40 → $45 | $33.36 | +34.89% | 6 | Oct 27, 2025 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $56 | $31.00 | +80.65% | 2 | Sep 24, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $30.70 | +176.92% | 2 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $5.98 | +568.90% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $238.46 | -83.23% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $3.13 | +219.49% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $1.76 | +70.45% | 2 | Mar 1, 2023 |
Relmada Therapeutics
Mar 20, 2026
Maintains: Outperform
Price Target: $10 → $19
Current: $7.29
Upside: +160.63%
Sarepta Therapeutics
Mar 13, 2026
Maintains: Outperform
Price Target: $26 → $31
Current: $21.18
Upside: +46.36%
uniQure
Mar 11, 2026
Upgrades: Outperform
Price Target: $12 → $35
Current: $15.38
Upside: +127.57%
Arcutis Biotherapeutics
Mar 2, 2026
Maintains: Outperform
Price Target: $37 → $35
Current: $24.21
Upside: +44.57%
ACADIA Pharmaceuticals
Feb 23, 2026
Upgrades: Outperform
Price Target: $29 → $35
Current: $21.74
Upside: +60.99%
Neurocrine Biosciences
Dec 12, 2025
Maintains: Neutral
Price Target: $146 → $175
Current: $128.89
Upside: +35.77%
Evolus
Dec 2, 2025
Maintains: Outperform
Price Target: $20 → $19
Current: $4.27
Upside: +344.96%
Alkermes
Oct 27, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $33.36
Upside: +34.89%
MBX Biosciences
Sep 24, 2025
Maintains: Outperform
Price Target: $38 → $56
Current: $31.00
Upside: +80.65%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $30.70
Upside: +176.92%
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $5.98
Upside: +568.90%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $238.46
Upside: -83.23%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $3.13
Upside: +219.49%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $1.76
Upside: +70.45%